Novartis AG ADR
USUSDNovartis AG ADR (XETRA:NOT) — Drug Manufacturers - General. Liczba giełd, na których notowane są akcje spółki: 7. Na tej stronie — cena i wykres, dywidendy, najwięksi akcjonariusze oraz historia liczby akcji.
O firmie
- Strona
- novartis.com
- Sektor
- Healthcare · Drug Manufacturers - General
- Siedziba
- BASEL, Switzerland
- Prezes
- Dr. Vasant Narasimhan M.D.
- Pracownicy
- 75 267
- Założona
- 1996
- Akcje w obrocie
- 1.91 mld na 2025-12-31
- Free float
- 1.86 mld
- Kapitalizacja rynkowa
- 276.48 mld USD
- Insiderzy
- 0.01%
- Inwestorzy instytucjonalni
- 7.27%
- Branża (SIC)
- Pharmaceutical Preparations
- Forma prawna
- MVII
- ISIN
- CH0012005267
- LEI
- 5493007HIVTX6SY6XD66
- Stopa wypłaty
- 56.0%
- FCF
- 17.6 mld USD44%
- Dług
- 29.4 mld USD1.0 l. FCF
- Staż dywidendowy
- 20 l.
- Zysk, FCF i wypłacone dywidendy — za 12 miesięcy do 31.12.2025 (najnowszy raport spółki).
Opis
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Giełdy i tickery
| Giełda | Ticker | Waluta | Cena | Typ |
|---|---|---|---|---|
| US USA Stocks | NVSEF OTC | USD | 135.75 +1.14% | akcje zwykłe |
| LSE London Stock Exchange | 0QLR IOB | CHF | 82.63 +0.00% | akcje zwykłe |
| MI Borsa Italiana (Milan) | 1NOVN dodatkowe | EUR | 127.94 +1.33% | akcje zwykłe |
| SW SIX Swiss Exchange | NOVN główne | CHF | 119.8 -0.13% | akcje zwykłe |
| SW SIX Swiss Exchange | NOVNEE dodatkowe | CHF | 120.02 -1.80% | akcje zwykłe |
| VI Vienna Stock Exchange | NOVN dodatkowe | EUR | 127.32 -0.31% | akcje zwykłe |
| XETRA Xetra | NOT dodatkowe | EUR | 126.82 +0.48% | akcje zwykłe |
Dywidendy
Novartis AG ADR (NOT) wypłaca dywidendy raz w roku. W ciągu ostatnich 12 miesięcy wypłacono 3.9091 EUR za akcję (płatności: 1). To około 3.08% obecnej ceny akcji. Na podstawie historii wypłat następna data ex-dywidendy spodziewana jest około 09.03.2027. Lata nieprzerwanych dywidend: 20.
| Dzień ex | Wypłata | Kwota | % | Typ | Ticker |
|---|---|---|---|---|---|
| 2026-03-10 | — | 3.9091 EUR | 3.1/3.1 % | roczny | XETRA:NOT |
| 2025-03-11 | — | 3.6978 EUR | 2.9/2.9 % | roczny | XETRA:NOT |
Wiadomości w tym tygodniu
Brak jeszcze wiadomości ze strony spółki.
Najwięksi akcjonariusze
| Posiadacz | Udział | Akcje | Data raportu |
|---|---|---|---|
| VANGUARD STAR FUNDS-Vang… | 1.35% | 27.43 mln | 2026-07-31 |
| VANGUARD TAX-MANAGED FUN… | 0.9% | 18.24 mln | 2026-06-30 |
| Fisher Asset Management,… | 0.76% | 15.52 mln | 2026-06-30 |
| iShares Trust-iShares Co… | 0.67% | 13.69 mln | 2026-08-31 |
| Goldman Sachs TRT II-Gol… | 0.6% | 12.19 mln | 2026-07-31 |
| Artisan Partners Funds I… | 0.51% | 10.29 mln | 2026-06-30 |
| Dodge & Cox Funds-Dodge… | 0.44% | 8.9 mln | 2026-06-30 |
| Morgan Stanley | 0.43% | 8.73 mln | 2026-06-30 |
| Dimensional Fund Advisor… | 0.4% | 8.12 mln | 2026-06-30 |
| Fidelity Concord Street… | 0.35% | 7.12 mln | 2026-07-31 |
| Primecap Management Comp… | 0.32% | 6.59 mln | 2026-06-30 |
| iShares Trust-iShares MS… | 0.32% | 6.53 mln | 2026-08-31 |
| LOOMIS SAYLES & CO L P | 0.26% | 5.24 mln | 2026-06-30 |
| MFS Series Trust XVII-MF… | 0.26% | 5.22 mln | 2026-06-30 |
| Bank of America Corporat… | 0.24% | 4.91 mln | 2026-06-30 |
| VANGUARD SPECIALIZED FUN… | 0.23% | 4.66 mln | 2026-07-31 |
| VANGUARD CHESTER FUNDS-V… | 0.21% | 4.25 mln | 2026-06-30 |
| Franklin Resources, Inc. | 0.16% | 3.25 mln | 2026-06-30 |
| Blackrock Inc. | 0.15% | 3.05 mln | 2026-06-30 |
| Goldman Sachs Group Inc | 0.15% | 2.98 mln | 2026-06-30 |
| Northern Trust Corporati… | 0.14% | 2.79 mln | 2026-06-30 |
| DFA INVESTMENT DIMENSION… | 0.11% | 2.14 mln | 2026-04-30 |
| LOOMIS SAYLES FUNDS II-L… | 0.07% | 1.42 mln | 2026-06-30 |
| VANGUARD HORIZON FUNDS-V… | 0.06% | 1.21 mln | 2026-06-30 |
| Franklin Mutual Series F… | 0.06% | 1.19 mln | 2026-06-30 |
| JANUS INVESTMENT FUND-Ja… | 0.05% | 949 726 | 2026-06-30 |
| Principal Funds, Inc-Equ… | 0.05% | 945 091 | 2026-04-30 |
| Dimensional ETF Trust-Di… | 0.04% | 888 855 | 2026-04-30 |
| Franklin Mutual Series F… | 0.04% | 812 618 | 2026-06-30 |
| Dimensional ETF Trust-Di… | 0.04% | 716 836 | 2026-04-30 |
| Pacer Advisors, Inc. | 0.02% | 482 153 | 2026-06-30 |
| Partners Capital Investm… | 0% | 24 335 | 2026-06-30 |
| Paradigm Asset Managemen… | 0% | 21 514 | 2026-06-30 |
| Generali Investments Cee… | 0% | 15 729 | 2026-06-30 |
